Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDER9S)

Drug Name

Minnelide Drug Info

Synonyms

UNII-1CIV2UMO40; 1CIV2UMO40; 14-O-Phosphonooxymethyltriptolide disodium salt; CHEMBL3740500; Triptolide O-Methyl Phosphate Disodium Salt; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-C)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-((phosphonooxy)methoxy)-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)-; 1254702-87-8

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 46203139
CAS Number: CAS 1254702-87-8
TTD Drug ID: DMDER9S

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Heat shock protein 70 (HSP70)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AG-858	DMNQ5T2	leukaemia	2A60-2B33	Phase 2	[2]
AEG-33773	DMSBLOU	Diabetic neuropathy	8C0Z	Phase 2	[3]
Enkastim-ev	DMGLHYU	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
Minnelide 001	DM5VEN9	Gastric adenocarcinoma	2B72	Phase 1	[5]
BRX-005	DMTDWIE	Diabetic foot ulcer	BD54	Phase 1	[6]
AG-707	DM7PLMJ	Herpes simplex virus infection	1F00	Phase 1	[7]
H-103	DMRCHOU	Metastatic malignant neoplasm	2D50-2E09	Phase 1	[8]
NK-1001	DMZMQDN	Atrial fibrillation	BC81.3	Discontinued in Phase 2	[9]
Bimoclomol	DMOP95G	Diabetic complication	5A2Y	Discontinued in Phase 2	[10]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Heat shock protein 70 (HSP70)	TTHYBIX	HS71A_HUMAN; HS71B_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Preparation of a Heat Shock Proteins 70-based Vaccine from DC-tumor fusion cells. Methods Mol Biol. 2011; 787: 255-265.
3	Mitogen-activated protein kinase kinase kinase 12 (MAP3K12; DLK); c-jun N-terminal kinase (JNK). SciBX 2(11); doi:10.1038/scibx.2009.462. March 19 2009
4	Company report (Multimmune)
5	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6	Cardiovascular effects of BRX-005 comparison to bimoclomol. Life Sci. 2000 Aug 25;67(14):1783-9.
7	A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine. 2011 Nov 3;29(47):8530-41.
8	A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther. 2009 Mar;16(3):376-82.
9	Novel therapeutic targets in the management of atrial fibrillation. Am J Cardiovasc Drugs. 2014 Dec;14(6):403-21.
10	Bimoclomol elevates heat shock protein 70 and cytoprotects rat neonatal cardiomyocytes. Eur J Pharmacol. 2002 Jan 18;435(1):73-7.
11	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.